LUMISIGHT allergy risk under the microscope in 1,500 patients
NCT ID NCT07572162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study monitors 1,500 adults with breast cancer who receive LUMISIGHT during lumpectomy surgery. Researchers will track how often serious allergic reactions occur within 60 minutes of injection. No new drug is being tested; the goal is to better understand the safety of this already-approved imaging agent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LUMISIGHT (pegulicianine)
What this could lead to
If successful, this study will provide clearer safety data on allergic reactions to LUMISIGHT, helping doctors manage risks during breast cancer surgery.
What could go wrong
This is an observational study, not a treatment trial. It only measures side effects and does not test a new therapy or cure. Results may not change clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••